

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

BioSante Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, no par value per share

(Title of Class of Securities)

09065 V 10 4

(CUSIP Number)

December 31, 2000

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

/ / Rule 13d-1(b)

/ / Rule 13d-1(c)

/X/ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

(1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

King Cho Fung

(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) / /

Not Applicable

(3) SEC Use Only

(4) Citizenship or Place of Organization
Citizen of Hong Kong

Number of Shares (5) Sole Voting Power
Beneficially 4,225,000 (see Item 4)

Owned by -----
Each Reporting (6) Shared Voting Power
Person With: 100,000 (see Item 4)

(7) Sole Dispositive Power
4,225,000 (see Item 4)

(8) Shared Dispositive Power
100,000 (see Item 4)

(9) Aggregate Amount Beneficially Owned by Each Reporting Person
4,325,000 (see Item 4)

(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) / /
Not Applicable

(11) Percent of Class Represented by Amount in Row (9)
8.0%

(12) Type of Reporting Person (See Instructions)
IN

ITEM 1.

- (a) Name of Issuer
The name of the issuer is BioSante Pharmaceuticals, Inc.

- (b) Address of Issuer's Principal Executive Offices
The address of the principal executive offices of BioSante is 175
Olde Half Day Road, Suite 247, Lincolnshire, Illinois 60069.

ITEM 2.

- (a) Name of Person Filing
King Cho Fung

- (b) Address of Principal Business Office or, if none, Residence
The address of Mr. Fung's principal place of business is Room 2101,
Lyndhurst Tower, One Lyndhurst Terrace, Central Hong Kong.

- (c) Citizenship
Mr. Fung is a Hong Kong citizen.

- (d) Title of Class of Securities
The class of equity securities to which this Statement relates is
the common stock, no par value per share, of BioSante
Pharmaceuticals, Inc.

- (e) CUSIP Number
The CUSIP number of the common stock is 09065 V 10 4.

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a) / / Broker or dealer registered under section 15 of the Act
(15 U.S.C. 78o).
- (b) / / Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) / / Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
- (d) / / Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
- (e) / / An investment adviser in accordance with section
240.13d-1(b)(1)(ii)(E).
- (f) / / An employee benefit plan or endowment fund in accordance with
section 240.13d-1(b)(1)(ii)(F).
- (g) / / A parent holding company or control person in accordance with
section 240.13d-1(b)(1)(ii)(G).
- (h) / / A savings association as defined in section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813).
- (i) / / A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3).
- (j) / / Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Mr. Fung's beneficial ownership includes: (1) 2,850,000 shares of common stock; (2) 750,000 shares of common stock issuable upon exercise of a warrant; (3) 625,000 shares of class C stock which is convertible into 625,000 shares of common stock; and (4) 100,000 shares of common stock held by Vancouver Beanstalk Holdings, Inc. Mr. Fung is President and Chief Executive Officer of Vancouver Beanstalk Holdings, Inc.

(b) Percent of class:

8.0%. The foregoing percentage is calculated based on the 52,952,943 shares of common stock reported to be outstanding by BioSante on its most recently filed quarterly report on Form 10-QSB for the quarter ended September 30, 2000.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote
4,225,000

(ii) Shared power to vote or to direct the vote
100,000

(iii) Sole power to dispose or to direct the disposition of
4,225,000

(iv) Shared power to dispose or to direct the disposition of
100,000

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not Applicable.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not Applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable.

ITEM 10. CERTIFICATION
Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 22, 2001

Date

/s/ King Cho Fung

King Cho Fung